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This knowledge-based act1v1ty 1s targeted for all pharmacists and
is acceptable for 1.0 hour (0. 1 CEU) of continuing education credit
This course requires completion of the program evaluation and at
least a 70 percent grade on the program assessment questions.
ACPE Universal ACtlVlty Number (UAN): 0048-0000-11-002-H01-P
Objectives:
After completion of this program, the reader should be able to
1. lden!Jfy the pemnent latxlratory values and/or symptomatobgy required
for ant1retrov1ral therapy m1t1at1on 1n treatment-naive HIV patients.
2. Descnbe the hm1tat10ns of early versus deferred treatment for HIV
infection.
3. List the factors that 1m1t patent adherence to antiretroviral therapy.
4. Identify !he significant changes made to the newest version of the
NIH HIV treatment guidelines.

Abstract
Human immunodeficiency virus (HIV) targets CD4+ lymphocytes
a cntical component co proper funcllonmg of the human immune
system. HIV IS a significant public health concern, having resulted
mover 27 m1ll10n deaths since 1ts discovery. Currently. several
different treacment options exist. with combination ant1retrov1ra1
therapy (ART) at the forefront. Despite the success of ART therapy
there are number of problems, 1nclud1ng poor patient compliance.
Due to this, the appropnate time to m1t1ate therapy 1n the treatment na·ive patient 1s under continuous scrutiny. Recently, several
trials have demonstrated evidence suggesting that initiating ART
at high CD4+ counts m the treatment na·ive patient 1s beneficial
mpreventing outcomes such as progression to AIDS and death
due to complicabOns from HIV. This review will discuss two trials
influenaa1 n the recent change in The National Institute of Health's
guidelines on therapy for treatment na·ive patients. The trials
reviewed here are !he North Amencan AIDS Cohort CollaborabOn
on Research Design (NA-ACCORD) and the Antiretroviral Therapy
Cohort Collaboraoon (ART-CCI. Despite the success of therapy r
IS associated with many negall"le side effects and high cost which
may affect peuem compliance, lead to possible drug resistance and
result m treatment failure. Along with the new evidence presented
1n clinical tnals. these factors a so must be considered when 1n1aat1ng therapy 1n the treatment naive HIV patient.
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Background
Human immunodeficiency virus (HIV) infects cells of the immune system
and progressively leads to the destruction or deterioration of immune
funcllOn. 1 HIV normally infects humaris by targeting a type of white blood
cell known as C04+ T lymphocytes, which are nvolved in cell-mediated immunity. Viral particles bmd to spec1f1c receptors on the cell surface and fuse
wltl1 the cell. The wus can then enter the host cell and insert its viral DNA
into the normal DNA of the host, forcing the newly infected cell to produce
addlbOnal copies of HIV. These new coptes of HIV can go on to infect other
cells, leading to a progressive decline m the number and funcbOn of C04+
T lymphocytes and attenuation of the immune system. Alter causing a
significant decline in immune funct1an, HIV can progress mto a roore serious fonrn known as acquired immune deficiency syndrome (AIDS). AIDS is
clinically defined as a CD4 +count of less than 200 cells/mm 3 or a documented AIDS-<lefmmg illness. HIV represents one of the world's greatest
public health challenges, as 1t has claimed more than 27 million lives since
its discovery. The HIV/AIDS epidemic conllnues to take nearly 2 million
lives each year.2 More than 33 million peope w:irldwlde , uicluding almost
1millK>n m the United States alone, currently liw with HIV/AIDS. HIV can
be transmitted via a number of different mechanisms mcluding unprotected
sexual intercourse, contaminated blood transfus10ns, or the sharing of
conram1nated needles. Infected mothers also can transfer the VJrus to a
child dunng pregnancy. birth or breastfeeding. Certain pallent populations,
1nclud1ng men who have sex with men (MSM), Atncan Amencans. and
Hispamc/Latlno Amencans are at a d1Sproport10nately increased risk for
contracong the virus.
As a result of increased patient education on prevenbOn and protection, the
spread of HIV has decreased 1n recent years.3 However, the total number
of infected individuals continues to rise as they are idenbfied ea~ier and
treated with more advanced medication regimens. Anllretrov1ral therapy
(ART) blocks HIV's activity on CD4+ cells by targehng different stages in
the HIV lifecycle and decreasing the overall wal load 1n infected individuals.
HIV antiviral therapy includes a combmaoon of the following drug classes:
nucleoside reverse transcriptase inhibitors (NRTls), non-nucleoside reverse
transcriptase inhibitors (NNRTls), protease mh1bitors (Pis). fusK>n inhibitors (Fis), entry inhibitors, and mtegrase strand :ransfer inhibitors (INSTls).
ART 111volves vanous combinations of the anhVral drug classes. There are
three preferred reg1meris for treaonent na'1\le pallents 1n the current NIH
guidelines •The regimens include a 2-NRTI becktx>ne along wltl1 either an
NNRTI. Pl (nronavir boosted) or INSTI While the efficacy of anbretrov1ral
therapy 1n slowing the progressK>n of HIV and maintaining higher CD4+
counts has long been establ1Shed, there is disagreement about when such
therapy should be inmated. Over the pest decade, several large-scale chmcal tnals have studted the r1Sks and benefits of 1mna11ng ART at higher CD4+
counts, resultlng 1n chan9es to the NIH guidelines for anllretrov1ral therapy
mtreatment na·1ve HIV patients.
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NA-ACCO RD
The North Amencan AIDS Cohort Collaboration on Research and Design
(NA-ACCORD) evaluated the rate of death for treatment na·1ve pauents
who initiated ART therapy within different thresholds of CD4+ counts. 5
Patients in two different CD4 +count ranges, either 351-500 cells/mm3 or
greater than 500 cells/mm3 , were allowed to initiate or defer ART therapy
a~ a part or U1eir HIV 1Jea1111en1 whe11 e11lering l11e trial. Palienlli who
initiated ART therapy more than six months alter the start of the trial were
included in the deferred group. A total of 8 ,362 patients, were included
in the first analysis, [who contributed 23,977 person-years of follow-up),
which looked at patients whose baseline CD4+counts were between 351500 cells/mm3• ART therapy was initiated in 25 percent of patients within
six months, while the remaining 75 percent deferred therapy. The second
analysis included 9, 155 patients (who contributed 26,439 person-years
of follow-up) whose CD4+ count was greater than 500 cells/mm 3 at the
beginning of the trial. In this group, 24 percent of patients initiated therapy
early, and 76 percent deferred for greater than six months. The results
of this study were significant because they assessed HIV patients with
CD4+ counts above the guideline recommendation at that bme, which
did not recommend 1nit1ation of ART unbl CD4+ count decreased to less
than 350 cells/mm3• Throughout the study, the CD4+ counts and rate of
death for patients in each group were assessed. A statistically significant
increase 1n the nsk of death for pabents who deferred therapy was seen
in both patient groups. The relative risk of death was 69 percent higher
(P<0.001) for patients who deferred therapy with a CD4+ count of 351-500
cells/mm 3 and 94 percent higher in patients who deferred when their
CD4+ count was greater than 500 cells/mm3. The large patient population and significant duration of observation gave this trial strong external
validity and allowed death to be used as an endpoint rather than an HIV/
AIDS related biomarker. The deferment group in each CD4+ count range
essentially served as a control for t~e study and allowed for an effective
analysis of when to initiate ART therapy for patients based on their CD4+
count No randomization or blinding of study participants was done in this
study. However, the use of death as an endpoint limited the risk of bias
in the results. Relaove nsk ad1J5tments for confounding variable such as
intravenous drug use and hepatitis C infection were performed , although a
sensitivity analysis suggested that due to the size of the 01a1, confound1rig
would have had to have been unnaturally large to affect the results. These
adjusted refallve-nsk calculations also demonstrated an increased nsk of
mortality for the deferment group in each of the respective cohorts.
ART-CC
The Antiretroviral Therapy Cohort Collaboration (ART-CC) was an analysis
of 12 cohort studies performed in Europe and North America between
1995 and 2003.6 The study evaluated ART-na·1ve HIV patients and the
progression of their disease once ART was initiated. The trial evaluated five
prognostic variables indicaove of disease progression, including CD4+ cell
count, HIV-1-RNA level, in)3ction drug use (IOU), age, and clinical AIDS. A
total of 22,217 patients were included in the cohort database. From the initiation of ART, 20,379 of the patients were analyzed. Due to a lack of CD4+
cell counts between months three and nine during the trial, only 16,167
were included in the analysis from six months after initiation. For each of
the vanables, a hazard rat10 was calculated for patients who progressed to
AIDS before death and patients who died pnor to the progression to AIDS.
Alter five years, the risk for both endpoints , progression to AIDS followed
by death or deaUl alone, ranged from 5.6-77 µercent. For exarnµle, palienlS
who were less than 30 years old, were infected with HIV via some means
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other than IOU, had a CD4+ count of less than 350 oells/mm 3 at therapy
in111aoon and had an HIV-RNA level below 5 log copies/ml possessed only
a 5.6 percent nsk of death over a five-year period. Patients who were 50
years old or older, became infected with HIV via IOU, started ART with
chmcal AIDS and a CD4+count of less than 25 cells/mm3 , had an HIV1-RNA level equal to or greater than Slog coptestml and whose disease
hall proyresseu to AIDS llad a 77 f.JerGenl risk of deaU1 over Uie course of
the trial. The results of this study demonstrated the signiocance of CD4+
cell counts as an indicator of overall survival in HIV patients. The hazard
ratios (95 percent Cl) ranged from 0.18 for patients with a six-month CD4+
count of greater than 350 cells/mm3 to 0.75 for those with a six-month
CD4+ count ranging from 25-49 cells/mm3. This study demonstrated strong
internal validity due to its large size and adjustrrent in the hazard ratios for
confounding variables. A limitation of the study was the lack of causespecifrc mortality data for patients in each of the respective cohorts.
Updated Guidelines
Studies such as the NA-ACCORD analysis and ART-CC mal have contributed to the increasing evidence in support of early ART therapy rnitiaoon in
HIV patients. As a result of these and other similar mals, a panel from the
Department of Health and Human Services made signrficant changes to
the current ART therapy guidelines with the goal of provld1rig health care
professionals with recommendations for HIV treatment that reflected the
find1rigs of the most recent clinical trials. A full vers10n of the new 2010 NIH
guidelines can be viewed online at www.aidsinfo.nih.gov.4 Among the many
modifications to the guidelines , the panel made several suggested changes
to the timing of ART therapy initiation in treatment na·1ve patient Citing evidence of decreased mortality in the NA-ACCORD and ART-CC clinical trials, the panel now recommends initiating therapy in all patients with CD4+
counts 500 cells/mm3 or less. While the benefits of initiatirig therapy earlier
were clear1y demonstrated in the above clinical trials, the i:anel remained
concerned about the long-term impact of side effects on patient adherence
and the overall success of treatment. As a resul of the NA-ACCORD trial,
the panel also made a recommendation for patients with CD4+ counts of
greater than 500 cells/mm 3• However, given the lack of supporting evidence
from other cohorts or randomized clinical tnals, the panel chose 10 classify
1nrt1aoon of ART therapy in these patients as optional and someth1rig to be
considered on a case-by-case basis. In all recommendaoons made by the
panel, they stressed the importance of assessing each individual patient's
commitment to lifelong ART therapy and adequately explainirig the associated benefits and risks before initiating therapy.
Cost
Patients who choose to begin antiretroviral therapy as a part of their HIV
treatment are making a lifelong commitment to expensive medications.
One argument against initiating such high-priced medications earlier in
the course of HIV progression is that the costs of treatment will be unnecessarily increased. A 2001 study on the ccst effectiveness of antire trovrral treatment found that patients who initia:ed combination therapy at
500 cells/mm' could expect to live an average of 9.1years alter starting
treatment and would incur a lifetime medical cost of $104, 100.7 Patients
m the study who chose to defer treatment until therr CD4+ counts fell
below 200 cells/mm 3 were expected to live an add11Jonal 8.51 years at
a total treatment cost of $98,000. The results also showed an increase
in the number of opportunistic infections experienced by HIV patients
who deferreu a11li1e1rovira1 lilerapy. Over U1e course or rnany years of
treatment, the costs associated with initiating therapy early are relatJvely
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small compared to the demonstraJed increase in hie expectancy and
decrease in the nsk for opportunistic rnfectrons.

Conclusion
The benefits of rmnaong therapy at CD4+ counts above 350 cells/mm1
were clearly demonstrated by the NA-ACCORD and ART-CC rnals. and
the newly refined guidelines renect these new hndrngs. However. treating
HIV patients with ART therapy does have a number of lim1ta.tJons as well.
Anoretrovrral drug costs in the United States remain high, and regardless of tho CD4' count at which thoy aro m1tiatod, roproscnt a significant
firiancral burden for patients, insurance companies and government
programs Many classes of anbretroviral drugs also have serious potential
side effects that can lead to increased morbidity and decreased patient
adherence. A ratienrs adherence to their medrcatlOn regimen IS vital to
slowing the progression of HIV and improVlng h~ expeciancy. Most types
of anoretrovrral therapy include multiple dlfferen: classes of drugs, and
the resulnng pll burden can lead to lower rates of adherence m ratients,
especially those with higher CD4+ counts that may not be experiencing
an AIDS defining illness. Resistance to ant1retrov1ral drugs, commonly the
result of poor patient adherence, can hmrt treatment optJorlS for patients
as they progress through the disease as well. However, despite these and
other concerns, rt IS important to focus on the consrstently improved patient
outoomes demonstrated in early 1mt1atron group> from the reviewed clinical
rnals. Across almost all demographic groups, ~rtJc1pants who rnmated ART
therapy eartrer in the oourse of the d1Sease were more likely to live longer
and less likely to progress to clm1:al AIDS. The success of ART mHIV
ratJents IS dependent on a variety of different factors. and a careful assessment of the rlSks and benefits of treatment must be perfonned for re.bents
oonsldenng mltlating therapy at any point rn the progress10n of the d1Sease.
Phannacrsts and other health care professrorials must play an active role in
d1Scuss1ng the risks and benefits of treatment with patients and assessing
the readiness to make a lifelong co mm itment to anhretroviral therapy. The
most recent findings certainly do not signal the end of the debate on ART
therapy, and HIV treatment will undoubtedly continue to be the focus of
much d1Scuss10n and research in the future.

Patient Adherence and Adverse Events
Patient adherence to ART therapy was not addressed rn either study cited by
the updated treatment guidelines, bJt remains a concern for practitioners and
patients because 1td1rect1y correlates wrth treatment success. Specifically,
the most common cause of antiretrovrral treatment failure rn HIV patients IS
non-adherence Pill burden, timing, tolerability, cost and interactions au limn
pabent adherence. Zldovudine (AZT) was the first annretroviral medK:ation
brought to the market mthe 1980s. Patients were required to take AZT five
times darly and experienced a number of debditanng side effects. Although
newer, more tolerable antiretroviral jrug therapies continue to become avaiJ..
able, each current class of antiviral medicaoons has general side effects that
can affect pabentadherence. NRTls can cause m1tochondnal toxicity including lacbc acldos1S, hepabC steatosis and pancreatitis.• NNRTls can produce
rashes and hepabC dysfunction.'' Pis cause gastrointestinal disturbance
(nausea, vommng, diarrhea), bleedi~g problems, hepatotox1c1ty and metabolic
issues 1nclud1ng hypertrprdemra, fat maldistnbution and insulin resrstance. 4•
Enfuvrrtlde, currently the only Fl on the mar1<et, IS admrnrstered suocutaneously and can cause 1npc110n-s1te react10ns, bactenal pneumonia, ir1Somnia,
nausea and diarrhea u Hepatotoxrc1ty, fever, rash and upper respnatory tract
mfectJon are oommon side effects seen in maraviroc, an entry inhibitor.'·..
Raltegravrr IS an INSTI, the newest ::lass of HIV annretrov1ral drugs, and has
been associated with an mcrease ui total cholesterol." In addllJOn to tolerabttny, pdl burden also affects pabent adherence. The availability of combination annretrov1ral drugs has helped curb some of these adherence issues.
In add1t10n, drug-drug and drug-food interactions exist and are considered
in therapy and monitoring. Pharmacists play an important role in screening
for drug interactions, educating patients on side effects and the importance
of adherence, as well as screening 'or other health issues and administering
appropriate rmmumzatJons. Overall, patient adherence must be managed by
all chnictans, 1nclud1ng phannacists, rn oraer to prevent progress10n of the
drsease and improve qualny of llfe.
References
1 AlDS1nfo A ServlC9 of the U.S. Deranmentof Heallh and Human SerDrug Resistance
vices. HIV and Its Treatment What You Srould Know Heallh lnfonna·
oon for Pat10nts. UJX!ated December 2009. Accessed Dec. 6, 2010.
Annretrov1ral drug res1Stance IS an mportant conslderat10n in the treatment
2 WHO World Health Organization. 10 facts on HIV/AIDS.
of HIV panents because rt can have a signrfrcant rm pact on the success
of ART therapy and lead to increased mortalrty. 11· ' 4 Opponents of early
www.who.1ntlfeatures/factf1les/h1v/en/index html. Updated July 2010.
Accessed Dec. 6,2010.
antrretrov1ral inltlatJon claim that using these drugs early in the course of
3. CDC: Centers of Disease Control and Prevenoon. HIV 1n the United
HIV progress10n can increase the risk for resistance and 11m1t future treatStatas an overview. www.cdc.gov/h1v/topics/surve1llance/resourceslfactment optrons for panents.15 Resistance to antlretrovrral drugs IS caused by
sheets/us_overview.htm. Updated July 2010. Accessed Dec. 6, 2010.
mutations in the Viral rarticles that 'esult in different forms of HIV within
4 Aldsinfo Panel on Antiretroviral Gurdehnes for Adults and Adoan individual. Some of these variarts of HIV are more resistant to antiretlescents. Guidelines for the use of ant1retrov1ral agents m HIV-1
rov1ral drugs and can lead to a dee-ease in the effectiveness of treatment
One of the most uiHuential factors in developing resistance to antiretroviral
infected adults and adolescents. Departroont of Health and Human
Services. Dec. 1, 2009. 1-161. Available at aldsmfo.nih.gov/comentdrugs IS poor adherence to medK:ation regimens. Patients who choose to
files/AdultandAdolescentGL.JXlf. Accessed Dec. 6, 2010.
inmate therapy and are subsequen:ly poorly adherent expose themselves
5. K1tahata MM, Gange SJ, Abraham AG, Memman B, Saag MS, Justo annretrov1ral drugs but do not fully suppress the replication of the virus.
ooe AC, et al. Effect of earty versus deferred ant1retrov1ral therapy
The vrrus then can connnue to replcate in the presence of subtherapeubC
for HIV on survival. N Engl J Med. 2009 ,360 1815-1826.
drug concentratlOns, and the rrsk for mutant strains of the virus developing
6. Lippincott Williams & Wilkens. Prognosis of HIV-1-infected patients
is increased The nsk of developing resistance to three ma pr classes of
antrretrov1ral drugs, NRTls, NNRTls and Pis, has been shown to decrease
up to 5 years after initiation of HAART collaborative analysis of
prospective studies. AIDS. 2007 ;2 1 1185-1197
if treatment IS rnltlated at higher CD4+ counts. 16•17 In order to reduce the nsk
of drug resrstance and maximize the effectiveness of ant1retrov1ral therapy, 7. Viesen K, Dawson J. Anti-retrovrral rron-nucleoslda reverse tranpharmac1Sts and other clinicians mJst stress the importance of medicatlOn
scnptase rnh1b1tors. Revised 6 June 2005. Chnica.I Phannacology.
Gold Standara. 2011.
adherence to panents begrnmng treatment

5

THE P HARMACY AND

WELLNESS A Ev1ew

Volume two. Issue one

Ma-ch 2011

Recent Advances Spark Significant Guideline Change:
Antiretroviral Therapy (ART) at High CD4+ Counts in the Treatment Nai·ve Patient
8. Viesen K, Dawson J. Anti-retroviral protease inhibitors. Revised 6
October 2005. Clinical Pharmacology. Gold Standard, 2011.
9. Enfuv1rt1de [monograph]. Lex1-Componline. Lexi-Comp; 2011.
10. Marav1roc [monograph]. Lexi-Comp online. Lexi-Comp; 2011.
11. Raltegravir (monograph]. Lexi-Comp online. Lexi-Comp: 2011.
12. Schackman BR, Goldie SJ, Wemstem MC, Losina E, Zhang H,

Infectious Disease

5. The 2010 NIH Guidelines state that antiretroviral therapy should be
1111tiated in patients with each of the following CD4+ counts EXCEPT
a. 300 cells/mm3
b. 350 cells/mm3
c. 400 cells/mm3
d. 600 cells/mm3

Freed berg KA. Cost-effectiveness of earlier initiation of antiretrov1-

ral therapy for uninsured HIV-infected adults. Am J Public Health.
2001 ;91:1456-1463.
13. Havlir DV, Marschner IC, Hirs1 MS, Collier AC, Tebas P, Bassett
RL, et al. Maintenance antiretroviral therapies in HIV-infected sub~cts with undetectable plasma HIV RNA after triple-drug therapy. N
Engl J Med. 1998;339:1261-1268.
14. Richman DD, Morton SC, Wrin T, Hellmann N, Berry S, Shaprio MF,
et al. The prevalence of antiretroviral drug resistance in the United
States. AIDS 2004;181393- 1401.
15. Weinstein MC, Goldie SJ, Losina E, Cohen CJ, Baxter JD, Zhang H,
et al. Use of genotypic resistance testing to guide HIV therapy: clinical
impact and cost-effectiveness. Ann Intern Med. 2001.134 440-450.
16. Phillips AN, Leen c. Wilson A, Anderson J, Dunn D, Schwenk A, et
al. Risk of extensive v1rolog1cal failure to the three original antiretroviral drug classes over long-term follow-up from the start of therapy
in patients with HIV infection: an observational cohort study. Lancet
2007,370"1923- 1928.
17. Lucas GM. Antiretroviral adherence, drug resistance, viral fitness
and HIV disease progression: a tangled web is woven. J Antimicrob
Chemother. 2005;55413-4 16.
Assessment Questions
1. There are currently _ _ _ _ _ _ _ people in the United
States living with HIV/AIDS:
a. 500,000
b. 1 m1ll1on
c. 2 m1ll10n
d. 5 million

6. Results of a study conducted by Schackman et al published in 2001
suggested that patients initiating ART therapy at 500 cells/mm3 could
expect to live an additional _ _ years as a result of treatment
a. 9.1 years
b. 7.5 years
c. 6.3 years
d. 10.6 years
7. All of the following are considered to be limitations to patient adherence with antiretroviral therapy EXCEPT:
a. Pill burden
b. Cost of treatment
c. Requires inpatient administration
d. Side effects

8. Protease Inhibitors are associated with which of the following side
effects:
a. Upper respiratory tract infection
b. Insulin resistance
c. Insomnia
d. Renal failure
9. Wh1Ch of the fo llowing is considered a role of the pharmacist in improving patient adherence and limiting adverse effects with antiretroviral
drugs?
a. Administering appropriate immunizations
b. Screening for drug-drug and drug-food mteraclions
c. Educating patients on common side effects of their med1cat10ns
d. All of the above

2. All of the following patient populations are at an increased nsk of
contracting HIV EXCEPT:
a. Hispanic/Latino Amencans
b. Men who have sex with men (MSM)
c. African Americans
d. All of the above

10. One argument against earlier initiation of ART therapy IS that poor
patient adherence will lead to an increased nsk of:
a. Side effects from current medications
b. Clinically significant bleeding episodes
c. Liver transplantation
d. Resistance to antiretroviral drugs

3. Which of the following is NOT considered a preferred antiretroviral
treatment regimen for treatment naive patients
a. 2-NRTI + 1 Pl (ritonavir roosted)
b. 2-NRTI + 1 Fl
c. 2-NRTI + 1 NNRTI
d. 2-NRTI + 1 INSTI
4. Which of the followmg CD4+ count values is the minimum at which an
asymptomatic HIV-positive pacient would not be classified as an AIDS
patient
a. 500 ce1Umm3
b. 200 cells/mm3
c. 100 cells/mm3
d. 50 cells/ mm3

To receive continuing education credit for this program, you must
answer the above questions and fill out the evaluation form. Please visit
www.onu.edu/pharmacy to enter the required information. Please allow
two to three weeks for electronic distribution of your continuing education certificate , which will be sent to your valid e-mail address in PDF
format
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The program objectives were clear.
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Identify the pertinent laboratory values and/or symptomatology required for
antiretroviral therapy initiation in treatment-naive HIV patients.
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Describe the limitations of early versus defen-ed treatment for HIV infection.
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The program met your educational needs.

1

2

3

4

5

Content of the program was interesting.
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Material presented was relevant to my practice.

1
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The program met the stated goals & objectives;

List the factors that limit patient adherence to antiretroviral therapy.
Identify tl1e significant changes made to the newest version of the NIH HIV
treatment guidelines.
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